Drug profile · INN
SOY-DOME
hexachlorophene (SOY-DOME) is a bacterial enoyl-[acyl-carrier-protein] reductase inhibitor. Associated with ADIAL PHARMACEUTICALS, INC.. Route of administration: topical. Current US regulatory status: approved.
hexachlorophene (SOY-DOME) is a bacterial enoyl-[acyl-carrier-protein] reductase inhibitor. Associated with ADIAL PHARMACEUTICALS, INC.. Route of administration: topical. Current US regulatory status: approved.
Bacterial enoyl-[acyl-carrier-protein] reductase inhibitor
Primary target: Enoyl-[acyl-carrier-protein] reductase [NADH] FabI
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
US 12351653
Pharmaceutical compositions comprising novel cyclic peptides
US 12162837
Substituted 3-dialkylaminomethyl-piperidin-4-yl-benzamides and methods of making and using same
US 12059418
Plasmodial surface anion channel inhibitors for the treatment or prevention of malaria
US 11884932
In vitro production of medial ganglionic eminence precursor cells
US 11851503
Antiplasmodial compounds
US 11725217
Methods to enhance myocardial regeneration and/or repair
US 11530240
Catheter injectable cyclic peptide pro-gelators for myocardial tissue engineering
US 11319290
Substituted 3-dialkylaminomethyl-piperidin-4-yl-benzamides and methods of making and using same
US 11230569
Antiplasmodial compounds
US 11141496
Use of berberine or derivative thereof in preparing myocardial perfusion imaging agent
US 10927135
Metal-free direct arylation of dialkyl phosphonates for the synthesis of mixed alkyl aryl phosphonates
US 10881669
Inhibitors of the plasmodial surface anion channel as antimalarials
US 10869865
Plasmodial surface anion channel inhibitors for the treatment or prevention of malaria
US 10836728
Substituted 3-dialkylaminomethyl-piperidin-4-yl-benzamides and methods of making and using same
US 10760048
In vitro production of medial ganglionic eminence precursor cells
US 10682416
Epicardial-derived paracrine factors for repairing cardiac tissue
US 10639289
Application of neuraminidase and inhibitors thereof in myocardial ischemia and myocardial infarction
US 10265313
Plasmodial surface anion channel inhibitors for the treatment or prevention of malaria
US 10100279
In vitro production of medial ganglionic eminence precursor cells
US 9974796
Inhibitors of the plasmodial surface anion channel as antimalarials
🔒 Efpia on AI Across the Medicines Lifecycle: Governance, GxP and Regulatory Policy Insights
AI governance across the medicines lifecycle requires attention to five critical stages: planning and design, data collection and processing…
hexachlorophene (SOY-DOME) is a bacterial enoyl-[acyl-carrier-protein] reductase inhibitor. Associated with ADIAL PHARMACEUTICALS, INC.. Route of administration: topical. Current US regulatory status: approved.
SOY-DOME is a marketed brand name for hexachlorophene. Check FDA Drugs@FDA for the current US label holder and prescribing information.
hexachlorophene has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.